Publications

5891 Results

S2433: Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Authors
Safyan RA;Singh H;Guthrie KA;Sun V;Wadlow R;Gbolahan OB;Sohal D;Lowy AM;Ahmad S;Chiorean EG;Philip PA
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs TPS4264 TIP poster
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
S2433

SWOG S2107: randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated MSS, BRAFV600E metastatic colorectal cancer (mCRC)

Authors
Morris V
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 3504 oral
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
S2107

Role of pretreatment vitamin D insufficiency in racial disparity in taxane-induced peripheral neuropathy: Results from the SWOG S0221 trial

Authors
Nguyen-Hoang N;Chen CS;Zirpoli G;Budd GT;Pusztai L;Hortobagyi GN;Albain KS;Godwin AK;Thompson A;Henry NL;Ambrosone CB;Stringer KA;Hertz DL
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 12136 poster
Year
2026
Research Committee(s)
Breast
Study Number(s)
S0221

The SWOG Mentoring Advanced Practice Providers (MAPP) program

Authors
Braun-Inglis CM
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs e21005 pub only e21005
Year
2026

Participation of Older Adults (=65 Years) in SWOG Cancer Clinical Trials

Authors
Parajuli J;McDermott JD;Bakitas M;Dizon DS
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 1543 poster 267; J Clin Oncol 44, 2026 (suppl 17; abstr 1543) DOI: 10.1200/JCO.2026.44.17_suppl.1543
Year
2026
Research Committee(s)
Cancer Care Delivery

Correlation of baseline testosterone (T) level with survival outcomes in patients (Pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)–level data from SWOG 1216 study

Authors
Gebrael G
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 5096 poster 191; J Clin Oncol 44, 2026 (suppl 16; abstr 5096) DOI: 10.1200/JCO.2026.44.16_suppl.5096
Year
2026
Research Committee(s)
Genitourinary
Study Number(s)
S1216

TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924)

Authors
Ong M
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs TPS5149 poster 235a; J Clin Oncol 44, 2026 (suppl 16; abstr TPS5149) DOI: 10.1200/JCO.2026.44.16_suppl.TPS5149
Year
2026
Research Committee(s)
Genitourinary
Study Number(s)
CCTG-PR26

Lycopene and survival in patients with stage III colon cancer: Findings from CALGB (Alliance)/SWOG 80702

Authors
Lee S
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 3630 poster 397; J Clin Oncol 44, 2026 (suppl 16; abstr 3630) DOI: 10.1200/JCO.2026.44.16_suppl.3630
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80702

Baseline CT-derived QVT score as predictor of bevacizumab benefit in advanced non-squamous NSCLC: A retrospective biomarker analysis of SWOG S0819

Authors
Zhang K
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 8549 poster 339; J Clin Oncol 44, 2026 (suppl 16; abstr 8549) DOI: 10.1200/JCO.2026.44.16_suppl.8549
Year
2026
Research Committee(s)
Lung
Study Number(s)
S0819

Resistance to Immune Checkpoint Inhibitor Treatment in Non–Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators

Authors
Doroshow DB
Journal / Conference
Journal of Clinical Oncology. 2026 Jun 3; JCO2501896. DOI: 10.1200/JCO-25-01896
Year
2026
Research Committee(s)
Lung
Study Number(s)
LUNGMAP, S1400